Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Fibromyalgia Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Fibromyalgia Agents Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs quantity-limit approval for pregabalin (Lyrica) and milnacipran (Savella) products on the Boeing commercial formulary. It applies to requests exceeding the program limit when the prescriber provides support meeting the specified FDA-labeling and higher-dose criteria.

    Policy Summary
    PayerPrime Therapeutics
    PolicyFibromyalgia Agents Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit support for a qualifying exception when the requested quantity exceeds the program limit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11Target products covered
    9Pregabalin formulations and strengths
    2Milnacipran products
    30 daysStandard tablet supply

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Approval period

    Quantity-Limit Clinical Criteria

    Quantity-limit clinical criteria for approval

    Quantity-limit approval is granted when ONE of the following is met:

    Quantity-limit approval

    • Within program limit

      • The requested quantity (dose) does not exceed the program quantity limit.Does not exceed the applicable program quantity limit
    • Above-limit exception

      • The requested quantity (dose) exceeds the program quantity limit.Exceeds the applicable program quantity limit
      • ONE qualifying exception pathway

        • No maximum FDA-labeled dose

          • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
          • There is support for therapy with a higher dose for the requested indication.
        • Within maximum FDA-labeled dose

          • The requested quantity (dose) does not exceed the maximum FDA-labeled dose for the requested indication.Does not exceed the maximum FDA-labeled dose
          • There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
        • Above maximum FDA-labeled dose

    Request Requirements and Denial Conditions

    Prior Authorization

    Quantity-Limit Approval Criteria

    The quantity-limit request will be approved when the requested quantity (dose) does not exceed the program quantity limit, or when it exceeds the limit and one of the qualifying exception pathways is met. Approval is for 12 months.

    • Pathway A: The requested agent has no maximum FDA-labeled dose for the requested indication, and there is support for therapy with a higher dose.
    • Pathway B: The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication, and there is support explaining why the requested dose cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
    • Pathway C: The requested quantity exceeds the maximum FDA-labeled dose for the requested indication, and there is support for therapy with a higher dose.
    Documentation Required

    Support for Quantity-Limit Exception

    For a quantity-limit exception, submit support for the requested higher dose or quantity exception. The documentation must address the applicable exception pathway, including support for higher-dose therapy or why the requested quantity cannot be achieved with a lower quantity of a higher strength that remains within the program quantity limit.

    Product-Specific Quantity Limits

    Quantity limit
    ProductLyrica (pregabalin capsule 100 mg)
    Quantity limit180 capsules
    Supply period30 days
    Quantity limit
    ProductLyrica (pregabalin capsule 150 mg)
    Quantity limit90 capsules
    Supply period30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyFibromyalgia Agents Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit support for a qualifying exception when the requested quantity exceeds the program limit.
    SourceLink
    On This Page
    Quantity-Limit Clinical CriteriaRequest Requirements and Denial ConditionsProduct-Specific Quantity Limits
    The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.Exceeds the maximum FDA-labeled dose
  1. There is support for therapy with a higher dose for the requested indication.
    • Support must be provided for therapy with a higher dose when the requested dose exceeds the program limit, whether or not a maximum FDA-labeled dose exists for the indication.
    • When applicable, explain why a lower quantity of a higher strength cannot achieve the requested dose without exceeding the program quantity limit.
    Denial Risk

    Exceeds Quantity Limit Without Qualifying Exception

    A request that exceeds the program quantity limit is at risk for denial unless it meets one of the specified exception pathways and includes supporting documentation for the applicable rationale.

    • The requested quantity exceeds the program limit without support for higher-dose therapy.
    • The requested quantity does not exceed the maximum FDA-labeled dose, but no support explains why a lower quantity of a higher strength within the program limit cannot be used.
    • The requested quantity exceeds the maximum FDA-labeled dose without support for therapy with a higher dose.
    Quantity limit
    ProductLyrica (pregabalin capsule 200 mg)
    Quantity limit90 capsules
    Supply period30 days
    Quantity limit
    ProductLyrica (pregabalin capsule 225 mg)
    Quantity limit60 capsules
    Supply period30 days
    Quantity limit
    ProductLyrica (pregabalin capsule 25 mg)
    Quantity limit360 capsules
    Supply period30 days
    Quantity limit
    ProductLyrica (pregabalin capsule 300 mg)
    Quantity limit60 capsules
    Supply period30 days
    Quantity limit
    ProductLyrica (pregabalin capsule 50 mg)
    Quantity limit270 capsules
    Supply period30 days
    Quantity limit
    ProductLyrica (pregabalin capsule 75 mg)
    Quantity limit180 capsules
    Supply period30 days
    Quantity limit
    ProductLyrica (pregabalin solution 20 mg/mL)
    Quantity limit900 mL
    Supply period30 days
    Product strengths and quantity limit
    ProductSavella (milnacipran hydrochloride tablets)
    Available strengths12.5 mg, 25 mg, 50 mg, and 100 mg
    Quantity limit60 tablets
    Supply period30 days
    Quantity limit
    ProductSavella titration pack (milnacipran hydrochloride)
    Pack strengths12.5 mg, 25 mg, and 50 mg
    Quantity limit1 pack
    Supply period180 days